Recombinant Human COMMD8 protein(Met1-Lys183), His-tagged

• Cat.No.: COMMD8-360H
• Product Overview: Recombinant Human COMMD8 (AAH19826.1) (Met1-Lys183) was expressed in E. coli with a polyhistidine tag at the N-terminus.

Specification

• Species: Human
• Source: E.coli
• Tag: His
• Protein Length: 1-183 a.a.
• Form: Lyophilized from sterile 50mM Tris, 100mM NaCl, 10% Glycerol, pH 8.0. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
• Molecular Mass: The recombinant human COMMD8 consists of 198 amino acids and predicts a molecular mass of 23 KDa. It migrates as an approximately 21-24 KDa band in SDS-PAGE under reducing conditions.
• Purity: > 95 % as determined by SDS-PAGE
• Storage: Samples are stable for up to twelve months from date of receipt at -20°C to -80°C. Store it under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
• Reconstitution: It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 ug/ul. Centrifuge the vial at 4°C before opening to recover the entire contents.

Gene Information

• Gene Name: COMMD8 COMM domain containing 8 [ Homo sapiens ]
• Official Symbol: COMMD8
• Synonyms: COMMD8; COMM domain containing 8; COMM domain-containing protein 8; FLJ20502
• Gene ID: 54951
• mRNA Refseq: NM_017845
• Protein Refseq: NP_060315
• UniProt ID: Q9NX08

Case Study

Case 1: Nakai A, et al. J Exp Med. 2019

Lymphocyte movement is steered by GPCRs reacting to chemoattractants. After activation, they get phosphorylated by GRKs, with β-arrestins shaping the result. The exact targeting process was a mystery until now—we found that the COMMD3/8 complex acts as an adapter, connecting GRKs to these receptors and aiding lymphocyte movement. Without COMMD3 or COMMD8, B cell migration falters. With CXCR4 as a model, we saw the complex draw in GRK6, leading to receptor phosphorylation and activation of β-arrestin signaling, highlighting its role in immune response regulation.

Fig1. IP assay for the interaction between COMMD8 and COMMD3 in mouse spleen cells.

Fig2. IP assay for the interaction of Myc-tagged COMMD8 with HA-tagged GRK6 or GRK2 in 2PK-3 cells expressing Flag-tagged CXCR4 after stimulation with CXCL12.

Case 2: Ji D, et al. Biochem Biophys Res Commun. 2019

Long noncoding RNAs (lncRNAs) are tied to cancer. MNX1-AS1 ramps up in liver cancer (HCC) and is linked to worse outcomes. Lowering it slows HCC growth by sponging miR-218-5p, which boosts COMMD8, aiding in cancer progression. Bringing back COMMD8 negates the reduction effects. Essentially, MNX1-AS1 drives HCC aggression through the miR-218-5p/COMMD8 pathway.

Fig1. Luciferase reporter assay showed that miR-218-5p suppressed the activity of wt-COMMD8 reporter.

Fig2. Relative expression of COMMD8 in indicated cell lines.

Application

Recombinant COMMD8 protein is becoming an exciting focus in medical research because it plays a vital role in managing immune responses and cancer behavior. By understanding COMMD8, scientists are looking at ways to enhance immune system performance, which could lead to new treatments for conditions where immune function is weakened. This has big potential for designing therapies that help the body fight infections and cancer more efficiently. In cancer research, COMMD8 is intriguing because of its role in guiding how cancer cells move and spread. Imagine it as a sort of traffic cop for cells, and by adjusting its activity, there might be a way to slow down or block cancer's progression. This could pave the way for therapies that specifically target cancer spread, reducing damage to healthy tissues and making treatment more effective with fewer side effects. The possibilities surrounding COMMD8 make it a promising area for developing next-generation medical treatments.